Subclinical Hypothyroidism Following Imatinib Use in Nigerian BCR::ABL1-positive Chronic Myeloid Leukemia Patients: A Prospective Cohort Study

Background: Thyroid toxicity has been reported with tyrosine kinase inhibitors (TKIs) such as sunitinib and sorafenib, targeting angiogenic tyrosine kinase receptors. However, the effect of imatinib, a first-line TKI for chronic myeloid leukemia (CML) patients on the thyroid, has been inconclusive....

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Ibrahim Oluwaseun Ahmed, Muritala Abiola Asafa, Babatunde Ayodeji Adeagbo, Tewogbade Adeoye Adedeji, Christianah Mopelola Asaleye, Rahman Ayodele Bolarinwa, Muheez Alani Durosinmi
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wolters Kluwer Medknow Publications 2024-09-01
سلاسل:	Journal of Applied Hematology
الموضوعات:	bcr::abl1 chronic myeloid leukemia imatinib mesylate subclinical hypothyroidism
الوصول للمادة أونلاين:	https://journals.lww.com/10.4103/joah.joah_121_23
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!